Analyst Expectations for Cerevel Therapeutics Hldg's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Cerevel Therapeutics Hldg (NASDAQ:CERE) stock. The average price target is $34.4, implying an upside from the current price of $21.88. This average has decreased by 11.79% from the previous average price target of $39.00.
September 28, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a bullish outlook on Cerevel Therapeutics Hldg (NASDAQ:CERE) with an average price target of $34.4, implying an upside from the current price of $21.88.
The bullish outlook from analysts suggests that they believe the stock price will increase in the short term. The average price target is significantly higher than the current price, indicating potential for growth. However, the decrease in the average price target from the previous one suggests some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100